It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Follicular lymphoma (FL) is an indolent cancer of mature B-cells but with ongoing risk of transformation to more aggressive histology over time. Recurrent mutations associated with transformation have been identified; however, prognostic features that can be discerned at diagnosis could be clinically useful. We present here comprehensive profiling of both tumor and immune compartments in 155 diagnostic FL biopsies at single-cell resolution by mass cytometry. This revealed a diversity of phenotypes but included two recurrent patterns, one which closely resembles germinal center B-cells (GCB) and another which appears more related to memory B-cells (MB). GCB-type tumors are enriched for EZH2, TNFRSF14, and MEF2B mutations, while MB-type tumors contain increased follicular helper T-cells. MB-type and intratumoral phenotypic diversity are independently associated with increased risk of transformation, supporting biological relevance of these features. Notably, a reduced 26-marker panel retains sufficient information to allow phenotypic profiling of future cohorts by conventional flow cytometry.
Follicular lymphoma can transform to a more aggressive histology. Here, the authors use bulk and single cell analysis to create a 26 marker panel which could be used to profile FL samples and predict the risk of transformation using flow cytometry.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 BC Cancer Agency, Terry Fox Laboratory, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000)
2 BC Cancer Agency, Lymphoid Cancer Research, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000)
3 BC Cancer Agency, Lymphoid Cancer Research, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000); Institut Gustave Roussy, Drug Development Unit, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
4 BC Cancer Agency, Canada’s Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000)
5 BC Cancer Agency, Canada’s Michael Smith Genome Sciences Centre, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000); Simon Fraser University, Department of Molecular Biology and Biochemistry, Burnaby, Canada (GRID:grid.61971.38) (ISNI:0000 0004 1936 7494)
6 BC Cancer Agency, Molecular Oncology, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000)
7 BC Cancer Agency, Molecular Oncology, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000); Memorial Sloan Kettering Cancer Center, Epidemiology and Biostatistics, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)